BCM
VKTX icon

BlueCrest Capital Management’s Viking Therapeutics VKTX Stock Holding History

BlueCrest Capital Management’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-146,149
Closed -$639K – 1841
2018
Q1 		$639K Buy
+146,149
New +$809K 0.02% 647

Other funds holding VKTX

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BlueCrest Capital Management's VKTX Position: Q2 2018 in Review

BlueCrest Capital Management sold out of Viking Therapeutics (VKTX) in Q2 2018, closing a stake of 146,149 shares — an estimated $639K sold.

BlueCrest Capital Management first reported a position in VKTX in Q1 2018 and held it in 1 quarter. The position peaked at $639K in Q1 2018. 116 funds tracked by Wall St. Rank hold VKTX as of Q2 2018.

  • BlueCrest Capital Management reported no remaining Viking Therapeutics position as of Q2 2018 after selling out during the quarter.
  • BlueCrest Capital Management sold 146,149 Viking Therapeutics shares in Q2 2018, an estimated $639K.
  • BlueCrest Capital Management first reported a position in Viking Therapeutics in Q1 2018 and held it in 1 quarter.
  • BlueCrest Capital Management's Viking Therapeutics position peaked at $639K in Q1 2018.
  • 116 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2018.

Based on BlueCrest Capital Management's 13F filing for Q2 2018, filed 14 Aug 2018.